| Tchem | Bone morphogenetic protein receptor type-1A |
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6.
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008]
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008]
Comments
Property Summary
| Ligand Count | 3 |
| NCBI Gene PubMed Count | 124 |
| PubMed Score | 211.01 |
| PubTator Score | 133.33 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Juvenile polyposis syndrome | 7 | 7.013 | 3.5 |
| Craniofacial Abnormalities | 151 | 0.0 | 0.0 |
| Eye Abnormalities | 35 | 0.0 | 0.0 |
| Female Urogenital Diseases | 18 | 0.0 | 0.0 |
| Polyposis Syndrome, Hereditary Mixed, 2 | 1 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| astrocytoma | 1146 | 2.6e-15 |
| ovarian cancer | 8520 | 1.2e-07 |
| psoriasis | 6694 | 5.2e-07 |
| posterior fossa group A ependymoma | 468 | 8.9e-05 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.3e-04 |
| Astrocytoma, Pilocytic | 3081 | 2.1e-04 |
| osteosarcoma | 7950 | 9.5e-04 |
| Disease | Target Count |
|---|---|
| POLYPOSIS SYNDROME, HEREDITARY MIXED, 1 | 3 |
| Disease | log2 FC | p |
|---|---|---|
| astrocytoma | 1.100 | 2.6e-15 |
| Astrocytoma, Pilocytic | 1.200 | 2.1e-04 |
| atypical teratoid / rhabdoid tumor | 1.200 | 1.3e-04 |
| osteosarcoma | 1.441 | 9.5e-04 |
| ovarian cancer | -1.400 | 1.2e-07 |
| posterior fossa group A ependymoma | 1.100 | 8.9e-05 |
| psoriasis | -1.100 | 5.2e-07 |
MPQLYIYIRLLGAYLFIISRVQGQNLDSMLHGTGMKSDSDQKKSENGVTLAPEDTLPFLKCYCSGHCPDD 1 - 70 AINNTCITNGHCFAIIEEDDQGETTLASGCMKYEGSDFQCKDSPKAQLRRTIECCRTNLCNQYLQPTLPP 71 - 140 VVIGPFFDGSIRWLVLLISMAVCIIAMIIFSSCFCYKHYCKSISSRRRYNRDLEQDEAFIPVGESLKDLI 141 - 210 DQSQSSGSGSGLPLLVQRTIAKQIQMVRQVGKGRYGEVWMGKWRGEKVAVKVFFTTEEASWFRETEIYQT 211 - 280 VLMRHENILGFIAADIKGTGSWTQLYLITDYHENGSLYDFLKCATLDTRALLKLAYSAACGLCHLHTEIY 281 - 350 GTQGKPAIAHRDLKSKNILIKKNGSCCIADLGLAVKFNSDTNEVDVPLNTRVGTKRYMAPEVLDESLNKN 351 - 420 HFQPYIMADIYSFGLIIWEMARRCITGGIVEEYQLPYYNMVPSDPSYEDMREVVCVKRLRPIVSNRWNSD 421 - 490 ECLRAVLKLMSECWAHNPASRLTALRIKKTLAKMVESQDVKI 491 - 532 //
